In Largest Upfront Payment of its Kind, Pfizer Hooks Up with Merck KGaA
Insights - Pfizer (PFE) put up $850 million to partner with Merck KGaA on a number of immuno-oncology drugs.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Our Weekly Biotech Trading Roundup
Recap - As expected, Trillium Therapeutics (SCTPF)(TR.TO) announced this week an upcoming reverse-split, NASDAQ uplisting, and reiterated the timeline for bringing its SIRPaFc antibody-like fusion proteins into the clinic … Continue Reading
Read now
On Bluebird Bio After a Glimpse at Preliminary Lentiglobin Data
Research - Last week, preliminary data for bluebird bio (BLUE)’s Lentiglobin were released as part of the abstract dump for ASH in December (we wrote at length about this, here). Bluebird … Continue Reading
Read now
Take Advantage of this Trading Channel Before Year-End
Research - In the relative near-term, XOMA Corporation (XOMA) is guiding to complete and release results from EYEGUARD-B, a phase III study of the company’s lead drug candidate gevokizumab … Continue Reading
Premium
Dendreon Attempts to Square Up Debtload with Restructuring, Bankruptcy
Insights - Dendreon (DNDN) has filed for bankruptcy protection and reached agreement with a majority of its debtholders to convert to equity in the company.
Read nowOur Top Stories and Trades in Healthcare from the Week
Recap - This week was jam-packed with market-moving events in biotech, punctuated on Thursday afternoon with an accounting scandal of epic proportions at Salix Pharmaceuticals (SLXP), which makes up … Continue Reading
Read now
Salix’s Accounting Issues: Where There’s One Roach, There’s Usually More
Insights - In one of the most shocking accounting errors we’ve seen in pharma, Salix Pharmaceuticals (SLXP) reported on Thursday after the bell that it has nine months of … Continue Reading
Read now